Viability of BMDMs exposed to heme, FeNTA, and hemolytic RBCs in the presence or absence of Hx and DFO
| . | NT . | +Heme-BSA . | + Heme-Hx . |
|---|---|---|---|
| M0 | 89.07 ± 2.443 | 51.13 ± 5.032 vs NT P < .0001 | 86.25 ± 3.036 vs Heme-BSA P < .0001 |
| M1 | 63.88 ± 3.785 | 46.17 ± 2.569 vs NT P < .001 | 71.95 ± 2.737 vs Heme-BSA P < .0001 |
| M2 | 89.85 ± 1.699 | 52.08 ± 2.788 vs NT P < .0001 | 90.78 ± 0.895 vs Heme-BSA P < 00001 |
| +FeNTA | + FeNTA-DFO | ||
| M0 | 94.40 ± 0.503 | 72.03 ± 5.341 vs NT P < .05 | 90.23 ± 4.670 vs FeNTA P < .05 |
| M1 | 61.30 ± 6.584 | 45.07 ± 5.007 vs NT not significant | 55.65 ± 6.986 vs FeNTA not significant |
| M2 | 93.40 ± 1.320 | 73.13 ± 3.464 vs NT P < .01 | 88.80 ± 2.70 vs FeNTA P < .05 |
| +RBC | + RBC-Hx | ||
| M0 | 93.98 ± 0.349 | 83.02 ± 0.837 vs NT P < .0001 | 88.75 ± 0.150 vs RBC P < .001 |
| . | NT . | +Heme-BSA . | + Heme-Hx . |
|---|---|---|---|
| M0 | 89.07 ± 2.443 | 51.13 ± 5.032 vs NT P < .0001 | 86.25 ± 3.036 vs Heme-BSA P < .0001 |
| M1 | 63.88 ± 3.785 | 46.17 ± 2.569 vs NT P < .001 | 71.95 ± 2.737 vs Heme-BSA P < .0001 |
| M2 | 89.85 ± 1.699 | 52.08 ± 2.788 vs NT P < .0001 | 90.78 ± 0.895 vs Heme-BSA P < 00001 |
| +FeNTA | + FeNTA-DFO | ||
| M0 | 94.40 ± 0.503 | 72.03 ± 5.341 vs NT P < .05 | 90.23 ± 4.670 vs FeNTA P < .05 |
| M1 | 61.30 ± 6.584 | 45.07 ± 5.007 vs NT not significant | 55.65 ± 6.986 vs FeNTA not significant |
| M2 | 93.40 ± 1.320 | 73.13 ± 3.464 vs NT P < .01 | 88.80 ± 2.70 vs FeNTA P < .05 |
| +RBC | + RBC-Hx | ||
| M0 | 93.98 ± 0.349 | 83.02 ± 0.837 vs NT P < .0001 | 88.75 ± 0.150 vs RBC P < .001 |
Cell viability was assessed by flow cytometry using 7AAD. Viability is reported as percentage viable cells over the total number of analyzed cells.